Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26170972
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Targeted therapy against cancer stem cells
#MMPMID26170972
Yang T
; Rycaj K
Oncol Lett
2015[Jul]; 10
(1
): 27-33
PMID26170972
show ga
Research into cancer stem cells (CSCs), which have the ability to self-renew and
give rise to more mature (differentiated) cancer cells, and which may be the
cells responsible for the overall organization of a tumor, has progressed rapidly
and concomitantly with recent advances in studies of normal tissue stem cells.
CSCs have been reported in a wide spectrum of human tumors. Like normal tissue
stem cells, CSCs similarly exhibit significant phenotypic and functional
heterogeneity. The ability of CSCs to self-renew results in the immortality of
malignant cells at the population level, whereas the ability of CSCs to
differentiate, either fully or partially, generates the cellular hierarchy and
heterogeneity commonly observed in solid tumors. CSCs also appear to have
maximized their pro-survival mechanisms leading to their relative resistance to
anti-cancer therapies and subsequent relapse. Studies in animal models of human
cancers have also provided insight into the heterogeneity and characteristics of
CSCs, helping to establish a platform for the development of novel targeted
therapies against specific CSCs. In the present study, we briefly review the most
recent progress in dissecting CSC heterogeneity and targeting CSCs in various
human tumor systems. We also highlight a few examples of CSC-targeted drug
development and clinical trials, with the ultimate aim of developing more
effective therapeutic regimens that are capable of preventing tumor recurrence
and metastasis.
free
free
free
